CDC ENTEBBE

West Nile virus, spreading across the US and Europe, has no vaccine or cure, causing thousands of infections annually with severe cases leading to neurological damage and death. Climate change exacerbates its spread, and despite vaccine trials, none have reached Phase 3. Anthony Fauci's recent hospitalization highlights the need for more research and funding.

Quad countries launch a cancer initiative in the Indo-Pacific, focusing on cervical cancer prevention, detection, and treatment. The initiative aims to improve health infrastructure, expand research collaborations, and support cancer care through various commitments from governments and non-government organizations.

FDA broadened approval of FluMist nasal spray for self-administration, making it the first influenza vaccine for home use, though availability is delayed until next flu season. AstraZeneca plans to sell FluMist directly to patients via an online pharmacy, pending prescription.

Neuralink's Blindsight implant for vision restoration gets FDA breakthrough designation. Discure raises $11M for bioelectronic device development. DeepLook Medical improves breast imaging with AI. FDA recalls infusion pumps from B. Braun and Fresenius Kabi. FDA to discuss generative AI devices in November. FDA releases draft guidance on biocompatibility assessment. Merit Medical buys Cook Medical's lead management portfolio for $210M. Axonics wins patent lawsuit against Medtronic. GE HealthCare gets FDA clearance for Alzheimer's imaging tool. Germitec launches US operations with FDA-cleared disinfection device.

FDA approves FluMist, a self-administered nasal spray flu vaccine for children 2-5 years old, offering convenience and accessibility. Vaccination is crucial for preventing flu-related complications, including hospitalizations and death. Common side effects include fever and nasal congestion.

FDA approves FluMist for self- or caregiver-administration for individuals aged 2 to 49 years to prevent influenza disease caused by subtypes A and B. The nasal vaccine, containing weakened live virus strains, can be administered by a healthcare provider or by the recipient or a caregiver aged 18 or older. This approval offers greater convenience and accessibility for vaccination against seasonal influenza.

Greenlane Holdings, Inc. (NASDAQ: GNLN) plans to launch fentanyl, xylazine, and drink spike detection test strips under the Safety Strips brand, available from September 25th. The global opioid overdose treatment market is expected to reach $1.54 billion in 2024, with a projected CAGR of 7.2% through 2034.

The House passed the BIOSECURE Act (HR 8333) 306-81, prohibiting executive agencies from contracting with entities using biotechnology equipment or services from companies of concern, specifically naming WuXi Apptec, MGI, BGI, and others. The bill, unamended from the House Committee version, is expected to be added to the Senate's annual defense bill. Critics argue the bill lacks due process and could disrupt supply chains, though 68% of U.S.-based life sciences companies are already adjusting operations with Chinese partners.

Fall brings flu and COVID-19 vaccines; CDC recommends everyone 6 months and older get both. Vaccines can be received simultaneously, and timing is flexible except for recent COVID-19 cases or prior vaccinations. RSV vaccine is not annual; only those 75+, 60-74 with specific conditions, or pregnant women need it. Annual flu and COVID-19 vaccines combat virus mutations. Vaccination in fall aligns with virus circulation patterns. Cancer and immunocompromised patients should get vaccines under medical supervision.